Details of the Drug

General Information of Drug (ID: DMAT2XH)

Drug Name

Nabumetone

Synonyms

NNB-001; NNB-004; NNB-005; Nabumetone (oral); Nabumetone (oral), Nobex; 6-MNA (oral), Nobex

Indication

Disease Entry	ICD 11	Status	REF
Pain	MG30-MG3Z	Approved	[1], [2]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

228.29

Topological Polar Surface Area (xlogp)

3.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Elimination: 0% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 6 - MNA hours [4]
Metabolism: The drug is metabolized via the aldo-keto reductase-1C family by corticosteroid 11-beta-dehydrogenase [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 125.154 micromolar/kg/day [6]
Vd: The volume of distribution (Vd) of drug is 5-10 L [7]
Water Solubility: The ability of drug to dissolve in water is measured as 0.015 mg/mL [3]

Chemical Identifiers

Formula: C15H16O2
IUPAC Name: 4-(6-methoxynaphthalen-2-yl)butan-2-one
Canonical SMILES: CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC
InChI: InChI=1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3
InChIKey: BLXXJMDCKKHMKV-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4409
ChEBI ID: CHEBI:7443
CAS Number: 42924-53-8
DrugBank ID: DB00461
TTD ID: D05CKR
INTEDE ID: DR1122
ACDINA ID: D00451

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase 2 (COX-2)	TTVKILB	PGH2_HUMAN	Inhibitor	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[9]
Cytochrome P450 1A2 (CYP1A2)_{Main DME}	DEJGDUW	CP1A2_HUMAN	Substrate	[10]
Aldo-keto reductase 1C1 (AKR1C1)	DE7P2FB	AK1C1_HUMAN	Substrate	[11]
Aldo-keto reductase 1C4 (AKR1C4)	DEAJN47	AK1C4_HUMAN	Substrate	[11]
Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)	DEZDRQO	DHI1_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Pain

ICD Disease Classification

MG30-MG3Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Prostaglandin G/H synthase 2 (COX-2)	DTT	PTGS2	7.93E-04	-0.29	-0.34
Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)	DME	HSD11B1	1.64E-01	1.14E-01	1.66E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	7.36E-01	1.62E-02	1.08E-01
Aldo-keto reductase 1C4 (AKR1C4)	DME	AKR1C4	4.05E-01	3.23E-02	2.28E-01
Aldo-keto reductase 1C1 (AKR1C1)	DME	AKR1C1	7.03E-02	6.23E-02	2.87E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	1.90E-01	-9.81E-03	-5.96E-02

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Nabumetone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Aspirin	DM672AH	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Nabumetone and Aspirin.	Pain [MG30-MG3Z]	[46]
-----------

Coadministration of a Drug Treating the Disease Different from Nabumetone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Nabumetone and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[47]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Nabumetone and Repaglinide.	Acute diabete complication [5A2Y]	[48]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Nabumetone and Glibenclamide.	Acute diabete complication [5A2Y]	[48]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Nabumetone and Tolazamide.	Acute diabete complication [5A2Y]	[48]
Nateglinide	DMLK2QH	Moderate	Increased risk of hypoglycemia by the combination of Nabumetone and Nateglinide.	Acute diabete complication [5A2Y]	[48]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Nabumetone and Glipizide.	Acute diabete complication [5A2Y]	[48]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Nabumetone and Inotersen.	Amyloidosis [5D00]	[49]
Cilostazol	DMZMSCT	Moderate	Increased risk of bleeding by the combination of Nabumetone and Cilostazol.	Arterial occlusive disease [BD40]	[50]
Budesonide	DMJIBAW	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Nabumetone and Budesonide.	Asthma [CA23]	[51]
Ofloxacin	DM0VQN3	Moderate	Additive CNS stimulant effects by the combination of Nabumetone and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[52]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Nabumetone and Kanamycin.	Bacterial infection [1A00-1C4Z]	[53]
Amikacin	DM5PDRB	Moderate	Increased risk of nephrotoxicity by the combination of Nabumetone and Amikacin.	Bacterial infection [1A00-1C4Z]	[53]
Norfloxacin	DMIZ6W2	Moderate	Additive CNS stimulant effects by the combination of Nabumetone and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[52]
ABT-492	DMJFD2I	Moderate	Additive CNS depression effects by the combination of Nabumetone and ABT-492.	Bacterial infection [1A00-1C4Z]	[52]
Gentamicin	DMKINJO	Moderate	Increased risk of nephrotoxicity by the combination of Nabumetone and Gentamicin.	Bacterial infection [1A00-1C4Z]	[53]
Netilmicin	DMRD1QK	Moderate	Increased risk of nephrotoxicity by the combination of Nabumetone and Netilmicin.	Bacterial infection [1A00-1C4Z]	[53]
Levofloxacin	DMS60RB	Moderate	Additive CNS stimulant effects by the combination of Nabumetone and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[52]
Tobramycin	DMUI0CH	Moderate	Increased risk of nephrotoxicity by the combination of Nabumetone and Tobramycin.	Bacterial infection [1A00-1C4Z]	[53]
Lomefloxacin	DMVRH9C	Moderate	Additive CNS stimulant effects by the combination of Nabumetone and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[52]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Nabumetone and Etidronic acid.	Bone paget disease [FB85]	[54]
Risedronate	DM5FLTY	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Nabumetone and Risedronate.	Bone paget disease [FB85]	[54]
Alendronate	DMY2KX9	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Nabumetone and Alendronate.	Bone paget disease [FB85]	[54]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of bleeding by the combination of Nabumetone and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[50]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Nabumetone and Iodipamide.	Cholelithiasis [DC11]	[55]
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Nabumetone and Levomilnacipran.	Chronic pain [MG30]	[56]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Nabumetone and Regorafenib.	Colorectal cancer [2B91]	[49]
Oxaliplatin	DMQNWRD	Moderate	Decreased renal excretion of Nabumetone caused by Oxaliplatin mediated nephrotoxicity.	Colorectal cancer [2B91]	[57]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Nabumetone and Drospirenone.	Contraceptive management [QA21]	[58]
Methoxyflurane	DML0RAE	Moderate	Increased risk of nephrotoxicity by the combination of Nabumetone and Methoxyflurane.	Corneal disease [9A76-9A78]	[49]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Nabumetone and Ardeparin.	Coronary thrombosis [BA43]	[59]
Rivaroxaban	DMQMBZ1	Major	Increased risk of bleeding by the combination of Nabumetone and Rivaroxaban.	Deep vein thrombosis [BD71]	[60]
Sertraline	DM0FB1J	Moderate	Increased risk of bleeding by the combination of Nabumetone and Sertraline.	Depression [6A70-6A7Z]	[56]
Fluoxetine	DM3PD2C	Moderate	Increased risk of bleeding by the combination of Nabumetone and Fluoxetine.	Depression [6A70-6A7Z]	[56]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Nabumetone and Vilazodone.	Depression [6A70-6A7Z]	[56]
Paroxetine	DM5PVQE	Moderate	Increased risk of bleeding by the combination of Nabumetone and Paroxetine.	Depression [6A70-6A7Z]	[56]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Nabumetone and Vortioxetine.	Depression [6A70-6A7Z]	[56]
Duloxetine	DM9BI7M	Moderate	Increased risk of bleeding by the combination of Nabumetone and Duloxetine.	Depression [6A70-6A7Z]	[56]
Milnacipran	DMBFE74	Moderate	Increased risk of bleeding by the combination of Nabumetone and Milnacipran.	Depression [6A70-6A7Z]	[56]
Escitalopram	DMFK9HG	Moderate	Increased risk of bleeding by the combination of Nabumetone and Escitalopram.	Depression [6A70-6A7Z]	[56]
Clomipramine	DMINRKW	Moderate	Increased risk of bleeding by the combination of Nabumetone and Clomipramine.	Depression [6A70-6A7Z]	[56]
PMID28870136-Compound-49	DMTUC9E	Moderate	Increased risk of bleeding by the combination of Nabumetone and PMID28870136-Compound-49.	Discovery agent [N.A.]	[61]
Fenfluramine	DM0762O	Moderate	Increased risk of bleeding by the combination of Nabumetone and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[56]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Nabumetone and Cannabidiol.	Epileptic encephalopathy [8A62]	[49]
Benzthiazide	DMQWZ0H	Moderate	Antagonize the effect of Nabumetone when combined with Benzthiazide.	Essential hypertension [BA00]	[62]
Tazemetostat	DMWP1BH	Moderate	Increased risk of bleeding by the combination of Nabumetone and Tazemetostat.	Follicular lymphoma [2A80]	[50]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Nabumetone and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[49]
Sulfinpyrazone	DMEV954	Moderate	Increased risk of bleeding by the combination of Nabumetone and Sulfinpyrazone.	Gout [FA25]	[50]
Eplerenone	DMF0NQR	Moderate	Antagonize the effect of Nabumetone when combined with Eplerenone.	Heart failure [BD10-BD1Z]	[63]
Chlorothiazide	DMLHESP	Moderate	Antagonize the effect of Nabumetone when combined with Chlorothiazide.	Heart failure [BD10-BD1Z]	[62]
Furosemide	DMMQ8ZG	Moderate	Antagonize the effect of Nabumetone when combined with Furosemide.	Heart failure [BD10-BD1Z]	[62]
Amiloride	DMRTSGP	Moderate	Antagonize the effect of Nabumetone when combined with Amiloride.	Heart failure [BD10-BD1Z]	[62]
Bumetanide	DMRV7H0	Moderate	Antagonize the effect of Nabumetone when combined with Bumetanide.	Heart failure [BD10-BD1Z]	[62]
Hydroflumethiazide	DMVPUQI	Moderate	Antagonize the effect of Nabumetone when combined with Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[62]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Nabumetone and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[64]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Nabumetone and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[65]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Nabumetone and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[66]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Nabumetone and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[67]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Nabumetone and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[68]
Indapamide	DMGN1PW	Moderate	Antagonize the effect of Nabumetone when combined with Indapamide.	Hypertension [BA00-BA04]	[62]
Trichlormethiazide	DMHAQCO	Moderate	Antagonize the effect of Nabumetone when combined with Trichlormethiazide.	Hypertension [BA00-BA04]	[62]
Hydrochlorothiazide	DMUSZHD	Moderate	Antagonize the effect of Nabumetone when combined with Hydrochlorothiazide.	Hypertension [BA00-BA04]	[69]
Dipyridamole	DMXY30O	Moderate	Increased risk of bleeding by the combination of Nabumetone and Dipyridamole.	Hypertension [BA00-BA04]	[50]
Potassium chloride	DMMTAJC	Moderate	Increased risk of hyperkalemia by the combination of Nabumetone and Potassium chloride.	Hypo-kalaemia [5C77]	[70]
Fludrocortisone	DMUDIR8	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Nabumetone and Fludrocortisone.	Hypo-osmolality/hyponatraemia [5C72]	[51]
Balsalazide	DMO091F	Moderate	Increased risk of nephrotoxicity by the combination of Nabumetone and Balsalazide.	Indeterminate colitis [DD72]	[71]
Ibandronate	DM0QZBN	Moderate	Increased risk of nephrotoxicity by the combination of Nabumetone and Ibandronate.	Low bone mass disorder [FB83]	[49]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Nabumetone and Porfimer Sodium.	Lung cancer [2C25]	[72]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of bleeding by the combination of Nabumetone and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[73]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Nabumetone and Idelalisib.	Mature B-cell leukaemia [2A82]	[74]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Nabumetone and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[75]
Clofarabine	DMCVJ86	Moderate	Increased risk of nephrotoxicity by the combination of Nabumetone and Clofarabine.	Mature B-cell lymphoma [2A85]	[49]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Nabumetone and Ibrutinib.	Mature B-cell lymphoma [2A85]	[76]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Nabumetone and Ponatinib.	Mature B-cell lymphoma [2A85]	[77]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Nabumetone and Exjade.	Mineral absorption/transport disorder [5C64]	[78]
Panobinostat	DM58WKG	Major	Increased risk of bleeding by the combination of Nabumetone and Panobinostat.	Multiple myeloma [2A83]	[47]
Deflazacort	DMV0RNS	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Nabumetone and Deflazacort.	Muscular dystrophy [8C70]	[51]
Ruxolitinib	DM7Q98D	Moderate	Increased risk of bleeding by the combination of Nabumetone and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[50]
Dasatinib	DMJV2EK	Major	Increased risk of bleeding by the combination of Nabumetone and Dasatinib.	Myeloproliferative neoplasm [2A20]	[79]
Omacetaxine mepesuccinate	DMPU2WX	Major	Increased risk of bleeding by the combination of Nabumetone and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[80]
Prasugrel	DM7MT6E	Major	Increased risk of bleeding by the combination of Nabumetone and Prasugrel.	Myocardial infarction [BA41-BA43]	[49]
Vorapaxar	DMA16BR	Major	Increased risk of bleeding by the combination of Nabumetone and Vorapaxar.	Myocardial infarction [BA41-BA43]	[81]
Tirofiban	DMQG17S	Moderate	Increased risk of bleeding by the combination of Nabumetone and Tirofiban.	Myocardial infarction [BA41-BA43]	[82]
Sibutramine	DMFJTDI	Moderate	Increased risk of bleeding by the combination of Nabumetone and Sibutramine.	Obesity [5B80-5B81]	[56]
Dexfenfluramine	DMJ7YDS	Moderate	Increased risk of bleeding by the combination of Nabumetone and Dexfenfluramine.	Obesity [5B80-5B81]	[56]
Metolazone	DMB39LO	Moderate	Antagonize the effect of Nabumetone when combined with Metolazone.	Oedema [MG29]	[62]
Polythiazide	DMCH80F	Moderate	Antagonize the effect of Nabumetone when combined with Polythiazide.	Oedema [MG29]	[62]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Nabumetone caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[83]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Nabumetone and MK-4827.	Ovarian cancer [2C73]	[49]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Nabumetone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[84]
Prednisone	DM2HG4X	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Nabumetone and Prednisone.	Postoperative inflammation [1A00-CA43]	[51]
Hydrocortisone	DMGEMB7	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Nabumetone and Hydrocortisone.	Postoperative inflammation [1A00-CA43]	[51]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Nabumetone and Epoprostenol.	Pulmonary hypertension [BB01]	[85]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Nabumetone and Iloprost.	Pulmonary hypertension [BB01]	[85]
Everolimus	DM8X2EH	Major	Increased risk of nephrotoxicity by the combination of Nabumetone and Everolimus.	Renal cell carcinoma [2C90]	[86]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Nabumetone and Temsirolimus.	Renal cell carcinoma [2C90]	[86]
Gatifloxacin	DMSL679	Moderate	Additive CNS stimulant effects by the combination of Nabumetone and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[52]
Sulfasalazine	DMICA9H	Moderate	Increased risk of nephrotoxicity by the combination of Nabumetone and Sulfasalazine.	Rheumatoid arthritis [FA20]	[71]
Dexamethasone	DMMWZET	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Nabumetone and Dexamethasone.	Rheumatoid arthritis [FA20]	[51]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Nabumetone and Leflunomide.	Rheumatoid arthritis [FA20]	[67]
Methylprednisolone	DM4BDON	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Nabumetone and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[51]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Nabumetone and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[49]
Prednisolone	DMQ8FR2	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Nabumetone and Prednisolone.	Solid tumour/cancer [2A00-2F9Z]	[51]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Nabumetone and Pitolisant.	Somnolence [MG42]	[49]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Nabumetone and Naltrexone.	Substance abuse [6C40]	[87]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of Nabumetone and Caplacizumab.	Thrombocytopenia [3B64]	[50]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Nabumetone and Apixaban.	Thrombosis [DB61-GB90]	[49]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Nabumetone and Cangrelor.	Thrombosis [DB61-GB90]	[50]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Nabumetone and Brilinta.	Thrombosis [DB61-GB90]	[49]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Nabumetone and Cabozantinib.	Thyroid cancer [2D10]	[88]
Sirolimus	DMGW1ID	Major	Increased risk of nephrotoxicity by the combination of Nabumetone and Sirolimus.	Transplant rejection [NE84]	[86]
Tacrolimus	DMZ7XNQ	Major	Increased risk of nephrotoxicity by the combination of Nabumetone and Tacrolimus.	Transplant rejection [NE84]	[86]
Chlorpropamide	DMPHZQE	Moderate	Increased risk of hypoglycemia by the combination of Nabumetone and Chlorpropamide.	Type 2 diabetes mellitus [5A11]	[48]
Olsalazine	DMZW9HA	Moderate	Increased risk of nephrotoxicity by the combination of Nabumetone and Olsalazine.	Ulcerative colitis [DD71]	[71]
Cinoxacin	DM4EWNS	Moderate	Additive CNS stimulant effects by the combination of Nabumetone and Cinoxacin.	Urinary tract infection [GC08]	[52]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Nabumetone and Plazomicin.	Urinary tract infection [GC08]	[53]
Nalidixic acid	DMRM0JV	Moderate	Additive CNS stimulant effects by the combination of Nabumetone and Nalidixic acid.	Urinary tract infection [GC08]	[52]
Enoxacin	DMYTE6L	Moderate	Additive CNS stimulant effects by the combination of Nabumetone and Enoxacin.	Urinary tract infection [GC08]	[52]
Triamcinolone	DM98IXF	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Nabumetone and Triamcinolone.	Vasomotor/allergic rhinitis [CA08]	[51]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Nabumetone and Betrixaban.	Venous thromboembolism [BD72]	[89]
-----------


⏷ Show the Full List of 119 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
D&C green no. 6	E00337	31416	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Carmellose sodium	E00625	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 200	E00648	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 19 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Nabumetone 500 mg tablet	500 mg	Oral Tablet	Oral
Nabumetone 750 mg tablet	750 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7245).
2	ClinicalTrials.gov (NCT01164826) Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's Under Fed Conditions. U.S. National Institutes of Health.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Jackson PJ, Brownsill RD, Taylor AR, Resplandy G, Walther B, Schwietert HR: Identification of trimetazidine metabolites in human urine and plasma. Xenobiotica. 1996 Feb;26(2):221-8. doi: 10.3109/00498259609046702.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Davies NM: Clinical pharmacokinetics of nabumetone. The dawn of selective cyclo-oxygenase-2 inhibition? Clin Pharmacokinet. 1997 Dec;33(6):404-16. doi: 10.2165/00003088-199733060-00001.
8	Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
9	In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone. Biol Pharm Bull. 2011;34(5):734-9.
10	A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes. Drug Metab Dispos. 2009 May;37(5):1017-24.
11	Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes. Eur J Drug Metab Pharmacokinet. 2015 Jun;40(2):127-35.
12	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
13	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
14	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
15	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
16	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
17	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
18	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
20	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
21	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
22	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
23	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
24	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
25	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
26	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
27	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
28	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
29	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
30	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
31	Human 3-alpha hydroxysteroid dehydrogenase type 3 (3alpha-HSD3): the V54L mutation restricting the steroid alternative binding and enhancing the 20alpha-HSD activity. J Steroid Biochem Mol Biol. 2014 May;141:135-43.
32	In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8.
33	The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
34	Characterization of enzymes participating in carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human placenta. Chem Biol Interact. 2001 Jan 30;130-132(1-3):737-48.
35	Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives. J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):213-22.
36	Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol. 2005 Aug;35(1):89-101.
37	Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
38	Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
39	Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
40	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
41	Pfizer. Product Development Pipeline. March 31 2009.
42	Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
43	Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
44	Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
45	Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur Respir J. 2009 Jul;34(1):200-8.
46	Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
47	Cerner Multum, Inc. "Australian Product Information.".
48	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
49	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
50	Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
51	Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
52	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
53	Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
54	Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
55	Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
56	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
57	Product Information. Eloxatin (oxaliplatin). Sanofi Winthrop Pharmaceuticals, New York, NY.
58	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
59	Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
60	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
61	Canadian Pharmacists Association.
62	Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
63	Abdel-Haq B, Magagna A, Favilla S, Salvetti A "Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects." J Cardiovasc Pharmacol 18 (1991): s33-6. [PMID: 1725198]
64	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
65	Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
66	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
67	EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
68	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
69	McCarthy JT, Torres VE, Romero JC, et al "Acute intrinsic renal failure induced by indomethacin." Mayo Clin Proc 57 (1982): 289-96. [PMID: 6952058]
70	Product Information. Potassium Chloride ER (potassium chloride). Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.
71	Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
72	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
73	Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
74	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
75	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
76	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
77	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
78	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
79	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
80	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
81	Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
82	Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
83	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
84	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
85	Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
86	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
87	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
88	Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
89	Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.